

**ChinaAMC Fund
(the “Fund”)**

**ChinaAMC China Opportunities Fund
(the “Sub-Fund”)**

NOTICE TO SHAREHOLDERS

This notice is important and requires your immediate attention. If you are in any doubt about the content of this notice, you should seek independent professional financial advice and/or legal advice.

All capitalized terms herein contained shall have the same meaning in this notice as in the Hong Kong Summary Prospectus dated June 2016, as amended from time to time (the “**Summary Prospectus**”).

June 2016

Dear Shareholder,

We are writing to inform you of the following changes concerning the Fund.

1. Clarification in relation to the requirements regarding the diversification of collateral

In the context of OTC financial derivatives transactions and efficient portfolio management techniques, the Fund may receive collateral with a view to reducing its counterparty risk.

As part of the collateral policy applied by the Fund, collateral must be properly diversified and the cash collateral received may be reinvested following the same diversification requirements. In particular, as disclosed in the Sub-Fund’s Summary Prospectus, the collateral, and cash collateral reinvested, if any, should be sufficiently diversified in terms of country, markets and issuers with a maximum exposure of 20% of the Sub-Fund’s net asset value to any single issuer on an aggregate basis, taking into account all collateral received.

With effect from 1 October 2014, the policy on reinvestment of collateral has been amended to provide that when the Sub-Fund is exposed to different counterparties in respect of OTC financial derivative transactions and transactions for efficient portfolio management techniques, the different baskets of collateral should be aggregated to

calculate the 20% limit of exposure to a single issuer.

Furthermore, the ESMA Guidelines 2014/937 and CSSF Circular 14/592 also enabled the Sub-Fund, by way of derogation from the rule above according to which a basket of collateral with an exposure to a given issuer cannot exceed 20% of the Sub-Fund's Net Asset Value, to be fully collateralised in different transferable securities and money market instruments issued or guaranteed by a Member State, its local authorities, a third country (member state of the OECD) or a public international body to which one or more Member States belong, provided that they receive transferable securities from at least six different issues, but transferable securities from any single issue should not account for more than 30% of the Sub-Fund's Net Asset Value.

In other words, while the Sub-Fund is subject to the 20% limit of exposure to a single issuer for the collateral received, the rule can be derogated to allow an exposure of up to 30% of the Sub-Fund's Net Asset Value to a single issue. The transferable securities and money market instruments covered by this derogation, must, as any collateral received be (inter alia) of high credit quality credit and highly liquid to be able to be used to reduce the Sub-Fund's counter party risk exposure in OTC financial derivative transactions and efficient portfolio management techniques.

2. Clarificatory updates to the settlement cycle

The disclosures on settlement procedures in the main part of the Summary Prospectus, which provide that cleared funds must be received by the Registrar and Transfer Agent on account of the Fund on the Dealing Day (i.e. each Business Day in Luxembourg and in Hong Kong) on which the subscription is processed, has been updated to be aligned with the disclosures in Appendix I of the Summary Prospectus relating to the Sub-Fund. For the avoidance of doubt, there is no change to the settlement cycle to the Sub-Fund (i.e. the payment for the Shares subscribed shall be received at the latest by 5pm Luxembourg time on the third Business Day following the Dealing Day).

3. Introduction of investors' right to terminate the nominee services and claim direct title of the purchased shares

Currently, Authorised Distributors may provide a nominee service to investors purchasing Shares of the Sub-Fund. Investors in the Sub-Fund may elect to make use of such nominee services, where available, pursuant to which the nominee will hold the Shares in its name for and on behalf of the investors.

With effect from the date of this Notice, investors will have the right to terminate the nominee services and claim direct title of the purchased shares, according to their contractual arrangement with the relevant Authorised Distributor.

4. Amendments resulting from implementation of UCITS V Directive

The Summary Prospectus has also been amended to reflect the requirements of the EU-Directive 2014/91 (the “**UCITS V Directive**”) as implemented in Luxembourg by the law dated 10 May 2016 (the “**UCITS V Law**”), which will enter into force on 1 June 2016. The UCITS V Law provides that certain provisions thereof regarding the Custodian’s functions and liability and the remuneration policy of the Management Company shall apply as from 18 March 2016. Details of the key amendments are set out below.

(a) Custodian’s functions and liability

Under the UCITS V Directive and the UCITS V Law, the functions and the liabilities of the appointed Custodian have been modified to be generally reinforced and increase the protection of investors. The Summary Prospectus has been amended to include, among other things, the functions and responsibilities of the Custodian, the duties and liabilities for acting as the Custodian, delegation of the safekeeping duties and other functions by the Custodian and the list of delegates and sub-delegates of the Custodian and conflicts of interests that may arise from such delegation. Up-to-date information on the foregoing is available to Shareholders on request at the registered office of the Custodian.

(b) The Remuneration Policy of the Management Company

Under the UCITS V Directive and the UCITS V Law, the remuneration of certain employees and members of the staff of the Management Company must be covered by a remuneration policy aiming at avoiding excessive risk taking, with a view to increase the protection of investors. A summary of the Management Company’s remuneration policy has been included in the Summary Prospectus to reflect the disclosure requirements of the UCITS V Directive. Details of the remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee, where such a committee exists, are available by means of a website [-https://www.fundrock.com/pdf/Fundrock_Remuneration_policy.pdf](https://www.fundrock.com/pdf/Fundrock_Remuneration_policy.pdf)¹ and from the registered office of the Management Company and the office of the Hong Kong Representative free of charge upon request from the date of this Notice.

5. Clarificatory updates to the section headed “Taxation”

Please note that the section headed “Taxation” of the Summary Prospectus have been updated to clarify or reflect changes in tax laws and regulations of Luxembourg, Hong Kong, China and other jurisdictions. Please refer to the Summary Prospectus

¹ This website has not been reviewed by the SFC and may contain information of funds not authorised by the SFC.

for details.

6. Change of Directors of the Fund

Fangjian Fu resigned as a director of the Fund on 1 December 2015 and with effect from 1 December 2015, Yanfang Cherian has been a director of the Fund.

7. Change of Directors of Management Company

Mr. Andy Wright resigned as a director of the Management Company on 31 December 2015, Mrs. Gudrun Goebel was appointed as a director of the Management Company on 25 July 2014 and with effect from 31 December 2015 and 13 April 2016, Mr. Eric May and Mr. Gregory Robinson-Kok have been the directors of the Management Company.

The Summary Prospectus and the Product Key Facts Statement of the Sub-Fund have been updated to reflect the above changes.

The Directors of the Fund accept full responsibility for the accuracy of the information contained in this notice at the date of publication. To the best of the knowledge and belief of the Directors of the Fund, having taken all reasonable care to ensure that such is the case, the information contained in this notice is in accordance with the facts and does not omit anything likely to affect the import of such information. The Directors accept responsibility accordingly.

Shareholders who have any enquiries regarding the above may contact the Hong Kong Representative at 37/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong or the enquiry hotline at (852) 3406 8686 during office hours.

Yours faithfully,

The Board of Directors of the Fund